Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Cardiotoxicity × Immunomodulating Agents × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Wilms Tumor 1 Neoplasms 1 Multiple Myeloma 1 Heart Diseases 1 Cardiotoxicity 1

Interventions

Doxorubicin 11 Razoxane 5 Dexrazoxane 5 Echocardiography 4 Cyclophosphamide 4 Vincristine 3 Trastuzumab 3 Granulocyte Colony-Stimulating Factor 3 Filgrastim 3 Etoposide 3 Electrocardiography 3 Radiotherapy 2 Prednisone 2 Methotrexate 2 Magnetic Resonance Spectroscopy 2 Exercise 2 Carvedilol 2 Bleomycin 2 salicylhydroxamic acid 1 oblimersen 1 hydrocortisone hemisuccinate 1 Vascular Stiffness 1 VAP-cyclo protocol 1 Tablets 1 Silymarin 1 Reverse Transcriptase Polymerase Chain Reaction 1 Resistance Training 1 Pulse Wave Analysis 1 Palliative Care 1 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡